IMDX · Insight Molecular Diagnostics Inc.
$4.32
+0.61 (+16.44%)
At close · Aug 14
Going-concern doubt
— cleared Aug 10, 2026
The latest filing states the doubt was alleviated.
“Our expectation to generate operating losses and negative operating cash flows in the future and the need for additional funding to support our planned operations raise substantial doubt regarding our ability to continue as a going concern for a period of one year after the date that the consolidated financial statements are issued. ... Management has concluded that it is probable that our plans will be effectively implemented and that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about our ability to continue as a going concern within one year after the date of issuance of these consolidated financial statements. ... Accordingly, management has concluded that substantial doubt does not exist about the Company's ability to continue as a going concern for a period of at least one year from the date of issuance of these consolidated financial statements.”View the 10-Q filed Aug 10, 2026
Market Cap
$141.37M
Shares
32.72M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Joshua Riggs | President & Chief Executive Officer | $2,594,786 |
| Andrea James | Chief Financial Officer | $1,679,126 |
| James Liu | VP of Accounting, Controller, Treasurer & PAO | $454,990 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Joshua Riggs | President and Chief Executive Officer | $786,077 |
| Andrea James | Chief Financial Officer | $758,863 |
| Ekkehard Schütz | Chief Science Officer | $633,568 |
| James Liu | Senior Director, Controller and Principal Accounting Officer | $303,928 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Joshua Riggs | President and Chief Executive Officer | $724,910 |
| Ekkehard Schütz | Chief Science Officer | $575,167 |
| Anish John | Former Chief Financial Officer | $449,161 |
| James Liu | Senior Director, Controller and Principal Accounting Officer | $304,513 |
| Andrea James | Chief Financial Officer | — |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Ronald Andrews | Former President and Chief Executive Officer | $2,352,595 |
| Gisela Paulsen | Former President and Chief Operating Officer | $1,341,125 |
| Douglas Ross | Former Chief Science Officer | $1,148,649 |
| Anish John | Former Chief Financial Officer | $738,162 |
| Joshua Riggs | President and Chief Executive Officer | $514,110 |
| James Liu | Controller and Principal Accounting Officer | $259,736 |
| Ekkehard Schütz | Chief Science Officer | — |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Ronald Andrews | Former President and Chief Executive Officer | $2,921,838 |
| Douglas Ross | Former Chief Science Officer | $1,640,137 |
| Mitchell Levine | Chief Financial Officer ^^ | $1,561,915 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Mitchell Levine | Chief Financial Officer ^^ | $1,058,460 |
| Ronald Andrews | President and Chief Executive Officer ^^ | $1,046,850 |
| Douglas Ross | Chief Science Officer | $980,437 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Ronald Andrews | President and Chief Executive Officer | $2,065,962 |
| Mitchell Levine | Chief Financial Officer | $1,157,937 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Louis E. Silverman | director | Appointed | 2026-06-17 |
| Andrew J. Last | director | Appointed | 2026-06-17 |
| Andrew Arno | director | Appointed | 2026-06-17 |
| Joshua Riggs | director | Appointed | 2026-06-17 |
| James Liu | Vice President Accounting, Controller, Treasurer and Principal Accounting Officer | Appointed | 2025-03-10 |
| Andrea James | Principal Financial Officer | Appointed | 2024-06-17 |
| Andrea James | Chief Financial Officer | Appointed | 2024-06-17 |
| James Liu | interim Principal Financial Officer | Appointed | 2023-08-10 |
| Joshua Riggs | Chief Executive Officer | Appointed | 2023-06-09 |
| Joshua Riggs | Board of Directors | Appointed | 2023-03-02 |
| Joshua Riggs | President | Appointed | 2023-03-02 |
| Joshua Riggs | Chief Executive Officer | Appointed | 2023-03-02 |
| Douglas Ross | Board | Resigned | 2022-12-21 |
| Gisela A. Paulsen, MPharm | officer and any and all other positions and/or titles with the Company | Resigned | 2022-12-21 |
| Gisela Paulsen | President and Chief Operating Officer | Terminated | 2022-12-21 |
| Joshua Riggs | Interim Chief Executive Officer | Appointed | 2022-12-05 |
| Louis E. Silverman | director | Appointed | 2022-12-05 |
| Joshua Riggs | Interim Chief Executive Officer | Appointed | 2022-12-05 |
| Melinda Griffith | Board | Resigned | 2022-11-23 |
| James Liu | Controller & Principal Accounting Officer | Appointed | 2022-09-26 |
| Anish John | Chief Financial Officer | Appointed | 2022-08-10 |
| Gisela Paulsen | President and Chief Operating Officer | Appointed | 2022-08-10 |
| John Peter Gutfreund | director | Appointed | 2022-08-01 |
| Li Yu | Vice President, Controller, and Principal Accounting Officer | Resigned | 2022-06-30 |
| Anish John | Senior Vice President, Finance, and Interim Chief Financial Officer | Appointed | 2022-05-11 |
Key facts
CIK
1642380
CUSIP
68235C206
13F (30d)
37 filings
37 filers
Visit website
Investor relations